MeasuredReferenceNeratinib targets EGFR, ERBB4_HER4, ERBB2_HER2. Strongest hallmark effect: tumor promoting inflammation.
Top hallmarks
- tumor promoting inflammation5.9k
- proliferation5.0k
- evading apoptosis4.8k
Top pathways disrupted
- apical junction10.6k
- allograft rejection10.3k
- pi3k akt mtor signaling9.8k
Resistance landscape — Neratinib
MeasuredReference10 known oncogenic variants exist on Neratinib's top targets — see detail for inhibition impact.